TXMD (TherapeuticsMD) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TXMD TherapeuticsMD Inc TXMD
55 GF Score
Price $2.07
GF Value $2.05
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is TherapeuticsMD Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

TXMD
55GF Score
TherapeuticsMD Inc TXMD
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TherapeuticsMD (TXMD) Overvalued in 2026?

Based on GuruFocus' analysis, TherapeuticsMD stock appears to be overvalued. The current stock price of $2.07 is trading 0.8% above its estimated GF Value™ of $2.05. GuruFocus considers TherapeuticsMD to be Fairly Valued.

Key valuation signals for TXMD:

  • Interest Received:
  • GF Value™: $2.05 vs. price of $2.07 (0.8% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the TXMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TherapeuticsMD Business Description

Other Exchanges 29TA:Germany
Address 951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
55GF Score

Get the complete analysis for TXMD

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.07
Price
$2.05
GF Value